Defunct Company
Total Trials
15
As Lead Sponsor
12
As Collaborator
3
Total Enrollment
4,755
NCT01137032
Study to Evaluate Effect of Pandel Cream 0.1% on HPA Axis in Pediatric and Adult Population
Phase: Phase 4
Role: Lead Sponsor
Start: Jun 30, 2004
Completion: Aug 31, 2005
NCT00546000
Cutivate Lotion HPA Axis Pediatric Study
Start: Jul 31, 2007
Completion: Dec 31, 2008
NCT01016782
Study of 0444 Gel in the Treatment of Inflammatory Lesions of Rosacea
Phase: Phase 3
Start: Jan 31, 2008
Completion: Jul 31, 2009
NCT01053247
Study of 0416 Ointment in the Treatment of Atopic Dermatitis
Completion: Aug 31, 2009
NCT01139450
Study of 0417 Ointment in the Treatment of Atopic Dermatitis
NCT00746382
A Placebo Controlled 4 Week Proof of Concept Study With 0.5% Roflumilast Cream in Patients With Mild Atopic Dermatitis (RO-2351-001-EM)
Phase: Phase 2
Role: Collaborator
Start: Nov 30, 2008
Completion: Sep 30, 2009
NCT00746434
A Proof of Concept Study With 0.5% Roflumilast Cream in Patients With Mild to Moderate Plaque Psoriasis
NCT00747032
To Demonstrate the Superior Efficacy of NYC 0462 Ointment Over That of the Placebo in the Treatment of Plaque Psoriasis
Start: Sep 30, 2010
Completion: Apr 30, 2011
NCT01232543
Safety Study Evaluating the Adrenal Suppression Potential of Product 0405 in Pediatric Subjects With Atopic Dermatitis
Start: Nov 30, 2010
Completion: Nov 30, 2011
NCT02147353
Treatment of External Genital Warts With Cryotherapy and Sinecatechins 15% Ointment
Phase: N/A
Start: Sep 30, 2011
Completion: Dec 31, 2012
NCT02176538
Study Comparing Product 0405 to a Vehicle Control in the Treatment of Mild to Moderate Atopic Dermatitis in Pediatric Subjects
Start: Jun 30, 2012
Completion: May 31, 2013
NCT02176551
NCT02176577
Study to Determine the Pharmacokinetics of Product 0405
NCT02886702
A Study Comparing Tazarotene Cream 0.05% to TAZORAC® (Tazarotene) Cream 0.05% and Both to a Placebo Control in the Treatment of Plaque Psoriasis
Start: Sep 19, 2016
Completion: Aug 2, 2017
NCT02886715
A Study Comparing Tazarotene Cream 0.1% to TAZORAC® (Tazarotene) Cream 0.1% and Both to a Placebo Control in the Treatment of Acne Vulgaris
Start: Sep 21, 2016
Completion: May 31, 2017